Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isatuximab with CyBorD and Lenalidomide in Newly Diagnosed Multiple Myeloma
NCT04786028Phase 2Active, not recruiting
- Sponsor
- Canadian Myeloma Research Group
- Start
- Dec 2021
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
A Phase 2 trial of isatuximab in multiple myeloma (MM), sponsored by Canadian Myeloma Research Group. Started Dec 2021; status: active, not recruiting.
02
Drugs
isatuximab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04786028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04786028.